Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study

(2021) Stefano Luminari et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

(2019) Ian W. Flinn et al.   JOURNAL OF CLINICAL ONCOLOGY

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

(2019) Emanuele Zucca et al.   BLOOD

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

(2018) Franck Morschhauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4

(2015) C C Bjorklund et al.   Blood Cancer Journal

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

(2014) Nathan H Fowler et al.   LANCET ONCOLOGY

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN

(2013) Anita K. Gandhi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

(2012) A Lopez-Girona et al.   LEUKEMIA